The FDA has giv­en the OK for Sarep­ta Ther­a­peu­tics to re­sume of­fer­ing its gene ther­a­py Ele­v­idys for am­bu­la­to­ry pa­tients with Duchenne mus­cu­lar dy­s­tro­phy. The agency said it con­clud­ed that the death of an 8-year-old boy was un­re­lat­ed to the gene ther­a­py it­self, but that gene ther­a­py re­mains paused in non-am­bu­la­to­ry pa­tients, fol­low­ing two pa­tient deaths...